<DOC>
	<DOCNO>NCT00720629</DOCNO>
	<brief_summary>The purpose study test whether new drug name visilizumab would decrease severity graft-versus-host disease patient treat mismatched donor . Investigators plan use visilizumab combination tacrolimus methotrexate `` study treatment '' .</brief_summary>
	<brief_title>Visilizumab Prevention Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation</brief_title>
	<detailed_description>The protocol plan two stage , control , phase II study ass safety compare grade acute graft-versus-host disease ( GVHD ) visilizumab , Anti-thymocyte Globulin ( ATG ) combination tacrolimus + methotrexate patient high risk GVHD transplant unrelated donor mismatch 1-2 allele type human leukocyte antigen ( HLA ) A , B , C DRB1 . The study design include two stage . The first stage trial enroll 15 patient single arm treat `` study treatment '' ( visilizumab , tacrolimus methotrexate ) ass treatment safety exclude intolerable GVHD . The second stage trial include random control group patient treat current `` standard treatment '' ( ATG , tacrolimus , methotrexate ) `` study treatment '' . The purpose comparison determine `` study treatment '' visilizumab cause less severe side effect potent reduce graft-versus-host disease symptom `` standard treatment '' .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>One follow diagnosis histological confirmation Pathology Department H. Lee Moffitt Cancer Center : Acute Lymphocytic Leukemia ( ALL ) complete remission 1 ( CR1 ) ( 9:22 ) ( 4:11 ) , ALL beyond CR1 Acute Myelogenous Leukemia ( AML ) high risk cytogenetics CR1 define Bloomfield AML beyond CR1 Myelodysplastic Syndrome ( MDS ) International Prognostic Scoring System ( IPSS ) score &gt; 1 Chronic myelomonocytic leukemia ( CMML ) Chronic Myelogenous Leukemia ( CML ) Imatinibrefractory chronic phase , beyond chronic phase morphology cytogenetics Myelofibrosis Severe aplastic anemia Chemosensitive NonHodgkin 's lymphoma Hodgkin 's disease candidate autologous transplant due prior autologous transplantation Multiple Myeloma patient candidate autologous stem cell transplantation Karnofsky performance status â‰¥ 70 % ( adult ) Normal organ marrow function define : Hepatic : Total bilirubin must less equal 2mg/dL ( Gilbert syndrome increase indirect bilirubin allow ) ; serum transaminase must less two time upper limit normal Pulmonary : diffusing capacity lung carbon monoxide ( DLCO ) ( correct Hgb ) , force expiratory volumeone second ( FEV1 ) , force vital capacity ( FVC ) must great 50 % predicted Cardiac : Left ventricular ejection fraction rest must great 50 % Renal : Creatinine clearance ( measure calculate ) must equal great 50 ml/min/1.73m^2 Anti thymocyte globulin ( ATG ) anti T cell therapy prior 45 day Splenectomized patient ; A positive pregnancy test administer female childbearing potential prior allogeneic stem cell transplant Inability comply follow determine patient 's physician HIVI/II infection prior hematopoietic stem cell ( HSC ) transplantation , confirm nucleic acid test ( NAT ) Uncontrolled bacterial fungal infection History document invasive aspergillosis cytomegalovirus ( CMV ) pneumonia Presence follow comorbid condition : History myocardial infarction Congestive heart failure ( even symptomatically control ) Peripheral vascular disease ( include intermittent claudication history bypass arterial insufficiency ) Untreated thoracic abdominal aneurysm ( 6cm ) History cerebrovascular accident include transient ischemic attack Dementia History peptic ulcer disease require treatment Connective tissue/rheumatologic disorder Diabetes unless manage dietary change Hemiplegia/paraplegia History solid tumor exclude skin cervical carcinoma curative resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>allogeneic transplant</keyword>
	<keyword>GVHD prevention</keyword>
	<keyword>unrelated donor</keyword>
	<keyword>mismatch unrelated donor</keyword>
	<keyword>hematological malignancy</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Aplastic Anemia</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>